Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006

Annals of Oncology

Volumn 19, Issue 3, 2008, Pages 481-486

  Ng, R ^a   Pond, G R ^b   Tang, P A ^a   MacIntosh, P W ^a   Siu, L L ^a   Chen, Eric X ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Breast cancer; Correlation; Disease free survival; Overall survival

Indexed keywords

ANTINEOPLASTIC AGENT; PREDNISONE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; HUMAN; MEDLINE; OUTCOME ASSESSMENT; OVARIECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

EID: 40149084173     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm486     Document Type: Article

References (21)

1. D.M. Parkin Global cancer statistics in the year 2000 Lancet Oncol 2 2000 533 543
2. American Cancer Society Cancer Facts and Figures. 2007 2007 American Cancer Society Atlanta, GA
3. G. Bonadonna A. Moliterni M. Zambetti 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study BMJ 330 2005 217 222
4. S. Gill D. Sargent End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? Oncologist 11 2006 624 629
5. D.J. Sargent H.S. Wieand D.G. Haller Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials J Clin Oncol 23 2005 8664 8870
6. T. Andre C. Boni L. Mounedji-Boudiaf Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343 2351
7. Food and Drug Administration Eloxatin: New or Modified Indication 2004 US Food and Drug Administration Washington, DC
8. P.E. Goss J.N. Ingle S. Martino A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 2003 1793 1802
9. R.C. Coombes L.S. Kilburn C.F. Snowdon Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 2007 559 570
10. B. Thurlimann A. Keshaviah A.S. Coates A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2005 2747 2757
11. A. Howell J. Cuzick M. Baum Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer Lancet 365 2005 60 62
12. J.R. Johnson G. Williams R. Pazdur End points and United States Food and Drug Administration approval of oncology drugs J Clin Oncol 21 2003 1404 1411
13. Early Breast Cancer Trialists’ Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
14. M. Buyse G. Molenberghs T. Burzykowski The validation of surrogate endpoints in meta-analyses of randomized experiments Biostatistics 1 2000 49 67
15. D.P. Petrylak D.P. Ankerst C.S. Jiang Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16 J Natl Cancer Inst 98 2006 516 521
16. R.L. Prentice Surrogate endpoints in clinical trials: definition and operational criteria Stat Med 8 1989 431 440
17. T.-M. Chu B. Weir R. Wolfinger A systematic statistical linear modeling approach to oligonucleotide array experiments Math Biosci 176 2002 35 51
18. H.J. Burstein Beyond tamoxifen—extending endocrine treatment for early-stage breast cancer N Engl J Med 349 2003 1857 1859
19. J. Bryant N. Wolmark Letrozole after tamoxifen for breast cancer—what is the price of success? N Engl J Med 349 2003 1855 1857
20. A.U. Buzdar P. Hietanen M. Makela Correspondence: letrozole in breast cancer N Engl J Med 350 2004 727 730
21. C.A. Hudis W.E. Barlow J.P. Costantino Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system J Clin Oncol 25 2007 2127 2132